Management of Pregnant Patient with Chronic Kidney Disease (CKD)

1. Background and Epidemiology

1. Severity of GFR reduction (serum creatinine at conception)
2. Presence and control of hypertension
3. Degree of baseline proteinuria

• Comprehensive Clinical Nephrology 7th Ed., p.641

2. CKD Staging and Risk Stratification in Pregnancy

Important: Neither the MDRD equation nor the CKD-EPI formula is valid in pregnancy. Serum creatinine is the standard monitoring tool. Normal pregnancy serum creatinine is ~0.6 mg/dL (50 µmol/L); a value of 0.8-0.9 mg/dL warrants investigation.

• Creasy & Resnik, p.1376

Maternal Outcomes by CKD Stage (Box 45.1 - Comprehensive Clinical Nephrology)

Fetal Outcomes by CKD Stage (Box 45.2)

• Preeclampsia: pooled aOR 2.58 (95% CI 1.33-5.01)
• Preterm birth: aOR 1.73 (1.31-2.27)
• SGA: aOR 1.93 (1.06-3.52)
• Cesarean delivery: aOR 1.65 (1.21-2.25)

3. Pre-Pregnancy Counseling

What to Cover (Box 45.4 - Comprehensive Clinical Nephrology)

• Accelerated GFR decline, potentially precipitating dialysis during/after pregnancy
• Severe hypertension with stroke risk
• Superimposed preeclampsia (hepatic, thrombotic, neurologic)
• Exacerbation of proteinuria/nephrotic syndrome with VTE risk

• FGR/IUFD from placental insufficiency
• Preterm delivery
• Drug teratogenicity/fetotoxicity
• Inherited kidney disorder (if relevant)

• Estrogen-containing preparations are generally contraindicated (hypertension, thrombosis risk)
• Progesterone-only methods (pill, implant, IUD) preferred
• Discuss fertility reduction in moderate-severe CKD (raised prolactin, reduced anti-Müllerian hormone)
• Single embryo transfer recommended with ART
• Comprehensive Clinical Nephrology 7th Ed., p.641

• Switch ACE inhibitors/ARBs to labetalol, nifedipine, or methyldopa
• Stop mycophenolate mofetil (teratogenic) - switch to azathioprine
• Stop methotrexate
• Stop statins
• Assess baseline proteinuria and creatinine for comparison

4. Multidisciplinary Team Structure

5. Antenatal Management Framework

• Blood pressure management targeting BP <135/85 mmHg
• Aspirin (75-150 mg/day) for all women with CKD
• Regular medication review: discontinue statins, ACE inhibitors, ARBs
• Correct interpretation of gestational changes in serum creatinine
• Clinical assessment and volume homeostasis
• Interpretation and management of proteinuria including nephrotic syndrome
• Identification of superimposed preeclampsia
• Identification/management of UTI
• Assessment of fetal well-being
• Consider indication for delivery

6. Blood Pressure Management

Targets

• UK Renal Association (2019): Target BP ≤135/85 mmHg throughout pregnancy (Grade 1D). Antihypertensive treatment should continue unless BP <110/70 mmHg consistently or symptomatic hypotension (Grade 2D).
• Comprehensive Clinical Nephrology 7th Ed.: BP <130/80 mmHg may be recommended to avoid suboptimal control periods, while avoiding sustained BP <110/70 mmHg.
• KDIGO Women and Kidney Health 2025: Targeting home BP to <130/80 mmHg is a reasonable objective.
• Indian Context (ISN/FOGSI-aligned): Target BP <140/90 mmHg is the minimum threshold; most nephrology consensus in India aligns with the UK guideline of <135/85 mmHg.

Safe Antihypertensive Agents in Pregnancy (Grade 1B, UK RA)

Strictly Contraindicated:

• ACE inhibitors and ARBs - impair fetal renal development, oligohydramnios, pulmonary hypoplasia, neonatal death
• Diuretics - not recommended (reduce plasma volume, compromise uteroplacental perfusion); exception: pulmonary edema

7. Pre-Eclampsia Prophylaxis and Diagnosis

Aspirin

• UK RA Guideline 4.3.1 (Grade 1B): Low-dose aspirin 75-150 mg daily should be offered to all pregnant women with CKD to reduce preeclampsia risk.
• KDIGO 2025 Conference Report: All pregnant women with CKD should receive prophylactic low-dose aspirin, started before 12 weeks' gestation.
• NICE/ACOG (referenced by KDIGO): Recommend aspirin for all high-risk patients - CKD qualifies as high risk.
• In India: FOGSI recommends low-dose aspirin for all high-risk pregnancies; CKD is explicitly a high-risk condition.

Diagnosing Superimposed Preeclampsia in CKD

8. Proteinuria Management

• Quantify proteinuria by uPCR or uACR - 24-hour urine is not required (UK RA Grade 1B)
• Baseline quantification before 20 weeks is recommended
• Proteinuria will typically worsen in pregnancy due to increased GFR, plasma flow, and stopping RAAS blockade
• Few therapeutic options during pregnancy apart from BP control

Nephrotic Syndrome in Pregnancy

• uPCR >300 mg/mmol (~protein >3 g/day) indicates nephrotic-range loss
• Serum albumin <30 g/L is common even in normal pregnancy - not reliable alone
• VTE prophylaxis with LMWH is recommended for:
  • All women with uPCR >300 mg/mmol (in absence of contraindications, and not delivering within 12 hrs)
  • Consider when uPCR 100-300 mg/mmol with additional VTE risk factors
• Warfarin is teratogenic - do not use during pregnancy
• Diuretics only for pulmonary edema
• Comprehensive Clinical Nephrology, p.642

9. Anemia Management

• Anemia is common in CKD - moderate-severe anemia occurs in >60% of women with stages 3-5 CKD in pregnancy
• Iron deficiency should be corrected - IV iron is safe in pregnancy (UK RA supports this)
• Erythropoiesis-stimulating agents (EPO/ESAs): Safe in pregnancy. If EPO was used before conception, the dose typically needs to be increased during pregnancy (UK RA guidelines).
• Target hemoglobin should be individualized; avoid over-correction
• Vitamin D supplementation: UK RA (Grade 1B) recommends supplementation for CKD women who are vitamin D deficient in pregnancy

10. Specific Kidney Disease Considerations

Diabetic Kidney Disease

• Highest-risk group because of coexisting vascular disease, impaired hemodynamic adaptation, glycemic risks
• Planning is essential: optimize BP, proteinuria (RAAS blockade before pregnancy, discontinue once pregnant)
• Intensive pre-conception glycemic and antihypertensive control improves outcomes
• Continuing RAAS blockade until conception and stopping at first missed period is an individualized but increasingly accepted approach
• NKF Primer 8th Ed., p.495

IgA Nephropathy

• Generally positive outcomes comparable to other CKD causes
• Increased risk: preterm birth (aOR 2.69), preeclampsia (aOR 4.29), SGA (aOR 1.84)
• Does not accelerate dysfunction in stages 1-2
• Proteinuria may increase in 3rd trimester; women with pre-pregnancy proteinuria have faster post-partum decline

Lupus Nephritis

• Must achieve remission for at least 6 months before conception (quiescent disease, minimal proteinuria, controlled BP)
• Mycophenolate mofetil is teratogenic - must switch to azathioprine before conception
• Hydroxychloroquine should be maintained throughout pregnancy (reduces flare frequency)
• Preeclampsia in lupus nephritis: occurs in ~two-thirds with preexisting renal involvement
• Active nephritis difficult to distinguish from preeclampsia - complement, anti-dsDNA help (low complement/rising anti-dsDNA favors lupus flare)
• In severe cases: pulsed corticosteroids + azathioprine; if severe disease at early gestation, iatrogenic preterm delivery may be necessary
• Creasy & Resnik, p.1378; NKF Primer 8th Ed., p.495

IgA Vasculitis / ANCA-Associated Vasculitis (GPA)

• Rare; 60% in remission at pregnancy start
• If active: prednisone + cyclosporine/azathioprine (pregnancy-safe combination)
• Cyclophosphamide and MMF require careful consideration due to teratogenicity

Reflux Nephropathy

• High risk for UTI/pyelonephritis - regular urine cultures throughout pregnancy
• Low-dose antibiotic prophylaxis may be warranted

11. Renal Biopsy in Pregnancy

• After 32 weeks: risk of bleeding increases significantly - biopsy generally avoided
• Indications during pregnancy: rapidly deteriorating kidney function, new nephrotic syndrome not explained by preeclampsia, vasculitis
• Post-partum biopsy preferred when gestational age allows waiting

12. Fetal Surveillance

• All pregnant women with CKD receive routine antenatal care plus specialist input (UK RA Grade 1D)
• Additional fetal surveillance:
  • Serial growth scans from 28 weeks (every 2-4 weeks for higher CKD stages)
  • Doppler velocimetry (uterine artery, umbilical artery) for FGR assessment
  • PlGF/sFlt-1 ratio where available for preeclampsia risk stratification
  • Cardiotocography (CTG) in the third trimester
• Amniotic fluid volume monitoring (oligohydramnios in severe uteroplacental insufficiency)

13. Timing and Mode of Delivery

• Mode and timing of birth are usually determined by obstetric factors
• Women with CKD can have vaginal delivery; CKD itself is not a cesarean indication
• If maternal complications arise before 34 weeks, attempt to continue pregnancy if possible (due to significantly better neonatal outcomes at ≥34 weeks)
• Maternal indications for iatrogenic preterm delivery:
  • Loss of maternal renal function
  • Symptomatic nephrotic syndrome including pulmonary edema
  • Refractory hypertension
  • Superimposed severe preeclampsia with systemic features

14. Dialysis in Pregnancy (CKD Stage 5 / ESKD)

• Intensified hemodialysis (increased frequency or duration) is associated with improved fetal outcomes - this is the standard approach for women on dialysis who are pregnant
• Targets: pre-dialysis BUN <30-40 mg/dL; longer weekly dialysis hours (>20 hours/week recommended)
• Peritoneal dialysis can be continued but becomes technically difficult as uterus enlarges
• Adequate nutrition and erythropoietin dose adjustment essential
• Many pregnancies on dialysis achieve live births with intensive monitoring
• Rosen's Emergency Medicine, p.670; Comprehensive Clinical Nephrology

15. Kidney Transplant Recipients in Pregnancy

• Allowed after at least 1-2 years post-transplant with stable graft function (serum creatinine <1.5 mg/dL), no recent rejection, stable immunosuppression
• Safe immunosuppressants in pregnancy (UK RA Grade 1B): prednisolone, azathioprine, ciclosporin, tacrolimus, hydroxychloroquine
• Calcineurin inhibitor (CNI) monitoring: Drug levels must be checked throughout pregnancy and immediately postpartum as concentrations change (UK RA Grade 1C)
• Mycophenolate mofetil: must be stopped and switched to azathioprine at least 6 weeks before conception
• Drugs interfering with CNI metabolism (erythromycin, clarithromycin) should be avoided
• Vaginal delivery is possible; cesarean for obstetric indications
• Breastfeeding is possible with pregnancy-safe agents

16. Postpartum Care

• BP often rises postpartum - monitor and treat to non-pregnant targets
• ACE inhibitors are safe in breastfeeding (captopril, enalapril preferred) - restart for antiproteinuric benefit
• ARBs: restart after lactation ceases
• Statins: can be restarted after breastfeeding
• All women with CKD or newly identified kidney disease in pregnancy need a clear postpartum follow-up plan - timing guided by CKD severity, BP, and drug monitoring needs
• Women with previously undiagnosed CKD should receive formal post-partum renal review
• UK RA: do not give NSAIDs postpartum to CKD patients (audit measure)

17. Indian Context - Special Considerations

1. FOGSI (Federation of Obstetric and Gynaecological Societies of India): High-risk pregnancy protocols; aspirin for preeclampsia prevention; iron supplementation (100 mg elemental iron for ≥180 days); vitamin D supplementation (400-600 IU/day due to high prevalence of deficiency in Indian women)
2. ISN (Indian Society of Nephrology): Broadly follows KDIGO 2024 and UK RA guidelines; specific Indian consensus exists for:
   • Lupus nephritis in pregnancy (given high SLE burden in Indian women of childbearing age)
   • Diabetic nephropathy management (India has among the world's highest T2DM burden)
   • IgA nephropathy (high prevalence in India compared to Western populations)
3. KDIGO 2024 CKD Guideline (Kidney Int. 2024;105[4S]:S117-S314, PMID 38490803): Now explicitly identifies pregnancy as a special population requiring individualized management; notes that evidence for optimal approaches in pregnant women with CKD remains limited.
4. KDIGO Women and Kidney Health Controversies Conference 2025 (PMID 40439632 - Piccoli et al., Kidney Int. 2025): Key recommendations:
   • All women with CKD should receive personalized preconception counseling from initial nephrology visit
   • Aspirin prophylaxis for all pregnant women with CKD
   • Home BP target <130/80 mmHg during pregnancy
   • Reproductive care embedded in dialysis and transplant protocols

18. Summary Algorithm

CKD diagnosed in a woman of reproductive age
        │
        ▼
PRECONCEPTION
• Multidisciplinary counseling (nephrologist + obstetrician)
• Switch ACE/ARB → labetalol/nifedipine/methyldopa
• Stop MMF → switch to azathioprine (at least 6 wks before conception)
• Stop statins, methotrexate
• Achieve BP <135/85, remission of any active disease (SLE ≥6 months)
• Baseline creatinine and proteinuria documentation
        │
        ▼
PREGNANCY CONFIRMED
• Confirm MDT care structure
• Start low-dose aspirin before 12 weeks
• Stop ACE inhibitors/ARBs immediately
• Quantify proteinuria (uPCR/uACR) before 20 weeks
• Monitor serum creatinine every 4-6 weeks
• Serial growth scans from 28 weeks
        │
        ▼
ONGOING ANTENATAL CARE
• BP target <135/85 mmHg (tighter target in proteinuric CKD)
• LMWH if uPCR >300 mg/mmol
• EPO dose adjustment for anemia
• IV iron if iron deficient
• VitD supplementation if deficient
• Vigilance for superimposed preeclampsia (modified criteria)
• PlGF monitoring after 20 weeks if high risk
        │
        ▼
DELIVERY DECISION
• Vaginal delivery preferred (CKD not indication for CS)
• Aim ≥34 weeks if possible
• Earlier if refractory HTN, deteriorating renal function,
  pulmonary edema, severe preeclampsia
        │
        ▼
POSTPARTUM
• Monitor BP - treat to non-pregnant targets
• Restart ACE inhibitor/ARB (not during breastfeeding for ARBs)
• Do not use NSAIDs
• Formal renal review plan for all
• Check CNI levels in transplant patients immediately postpartum

Key References

• International: UK Renal Association Clinical Practice Guideline on Pregnancy and Renal Disease (2019) - the most detailed and widely referenced
• KDIGO 2024 - CKD special populations chapter; KDIGO Women and Kidney Health 2025 Controversies Conference
• Textbooks: Comprehensive Clinical Nephrology 7th Ed., Creasy & Resnik's MFM, NKF Primer 8th Ed.
• Indian context: FOGSI high-risk pregnancy guidelines + ISN alignment with KDIGO; no separate Indian CKD-pregnancy guideline exists, but Indian physicians follow UK RA/KDIGO with adaptations for local disease patterns (high SLE prevalence, diabetic nephropathy, IgA nephropathy)